Jefferson University Hospitals

Physician Profile

John Wagner, MD

Jefferson University Physician

Academic Title: Professor
Clinical Director, Blood and Marrow Transplant Program

Specialties
Hematology - Medical Oncology
Medical Oncology
Medical Oncology - Bone Marrow Transplant
Medical Oncology - Hematologic Malignancies
Medical Oncology - Leukemia/Lymphoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Years in Practice

22

Board Certifications

  • Medical Oncology
  • Hematology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Notes

Dr. Wagner also specializes in Stem Cell Transplantation and Myeloma/Multiple Myeloma.

Education

  • Temple University School of Medicine, Medical School

Internship

  • University of Maryland Medical System

Residency

  • University of Maryland Medical System

Fellowship

  • Fred Hutchison Cancer Research Center

Recent Publications

Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome

Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization

A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation

A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease

Investigation of a Clostridium difficile cluster by multilocus sequence typing in a bone marrow transplant unit

Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation

Canine immunogenetics

A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing

Adenovirus DNA polymerase is recognized by human CD8+T cells

Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy

In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy

Port site metastasis of B-cell lymphoma: A first occurrence or an underreported complication?

Sequence of the canine major histocompatibility complex region containing non-classical class I genes

Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study

Activity of single-agent melphalan 220-300 mg/m2with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma

Cytoprotection in acute myelogenous leukemia (AML) therapy

Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation

Molecular Organization of the Canine Major Histocompatibility Complex

Cellular, serological, and molecular polymorphism of the class I and class II loci of the canine major histocompatibility complex

Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee